Price chart
Loading 1Y daily…
Financial overlay · last 12 quarters
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | $4.7B | $-0.3B | $0.6B | $0.5B | -6.6% | 13.3% |
| 2025-12-31 | $5.3B | $0.4B | $0.7B | $0.5B | 7.3% | 12.6% |
| 2025-09-30 | $5.9B | $0.5B | $0.8B | $1.0B | 8.4% | 14.0% |
| 2025-06-30 | $5.5B | $0.6B | $1.0B | $1.0B | 10.4% | 17.8% |
| 2025-03-31 | $4.5B | $0.3B | $0.5B | $0.0B | 6.9% | 10.6% |
| 2024-12-31 | $nanB | $nanB | $nanB | $nanB | nan% | nan% |
Earnings replay · last 20 reports
| Date | EPS actual | EPS est | Surprise |
|---|---|---|---|
| 2026-05-07 | 2.90 | 2.77 | +4.5% |
| 2026-02-09 | 1.34 | 0.26 | +415.4% |
| 2025-11-06 | 3.96 | 3.91 | +1.1% |
| 2025-08-07 | 3.68 | 3.40 | +8.2% |
| 2025-05-01 | 3.35 | 3.28 | +2.1% |
| 2025-02-05 | 3.43 | 2.99 | +14.7% |
| 2024-11-07 | 3.81 | 3.77 | +1.1% |
| 2024-08-01 | 3.50 | 3.31 | +5.8% |
| 2024-05-02 | 3.17 | 2.97 | +6.8% |
| 2024-02-01 | 2.68 | 2.40 | +11.6% |
| 2023-11-09 | 3.42 | 3.43 | -0.1% |
| 2023-08-03 | 2.96 | 2.91 | +1.6% |
| 2023-05-04 | 2.86 | 2.75 | +4.0% |
| 2023-02-02 | 2.98 | 2.68 | +11.0% |
| 2022-11-10 | 2.75 | 2.74 | +0.4% |
| 2022-08-04 | 2.66 | 2.50 | +6.5% |
| 2022-05-05 | 3.18 | 2.95 | +7.9% |
| 2022-02-03 | 3.64 | 2.85 | +27.5% |
| 2021-11-04 | 2.59 | 2.45 | +5.5% |
| 2021-08-05 | 2.74 | 2.44 | +12.2% |
Earnings markers are overlaid on the price chart above. Transcript summaries require PERPLEXITY_API_KEY (deferred to a follow-up).
Peer comparison · Healthcare
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| BDX ★ | $40B | 25.5 | 10.9 | 1.8 | 9.2 | 1.7 | 47.1% | 5.2% | — | 11.25% |
| LLY | $1,010B | 40.3 | 25.5 | 14.0 | 28.9 | 32.4 | 82.8% | 55.5% | 169.9% | 0.91% |
| UNH | $371B | 30.8 | 19.5 | 0.8 | 19.8 | 3.8 | 18.8% | 2.0% | 0.7% | 4.77% |
| JNJ | $580B | 27.9 | 18.9 | 6.0 | 17.9 | 7.1 | 68.0% | 9.9% | -52.9% | 2.16% |
| MRK | $294B | 33.5 | 12.4 | 4.5 | 11.4 | 6.4 | 76.7% | 4.9% | — | 4.78% |
| ABBV | $402B | 111.1 | 14.0 | 6.4 | 15.6 | -60.5 | 72.0% | 12.4% | -46.2% | 5.17% |
| PFE | $149B | 20.0 | 9.3 | 2.4 | 7.9 | 1.7 | 74.8% | 5.4% | -10.1% | 8.29% |
| TMO | $174B | 25.8 | 17.2 | 3.9 | 19.0 | 3.3 | 40.9% | 6.2% | 11.3% | 3.17% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Top institutional holders
Top-10 concentration: 46.6%
| Holder | Shares | % out |
|---|---|---|
| Blackrock Inc. | 26,153,411 | 9.49% |
| Vanguard Capital Management LLC | 18,490,610 | 6.71% |
| Vanguard Portfolio Management LLC | 15,317,242 | 5.56% |
| State Street Corporation | 13,822,808 | 5.02% |
| First Eagle Investment Management, L | 11,928,111 | 4.33% |
| Invesco Ltd. | 10,174,327 | 3.69% |
| T. Rowe Price Investment Management, | 9,685,271 | 3.52% |
| Massachusetts Financial Services Co. | 9,101,454 | 3.30% |
| Geode Capital Management, LLC | 7,107,263 | 2.58% |
| Wellington Management Group, LLP | 6,615,230 | 2.40% |
Insider activity · 90d
5 buys / 6 sells · ratio 0.83 · Finnhub
- Garrison Michael David SELL 14,272 @ $151.48
- Polen Thomas E Jr M 0
- Polen Thomas E Jr SELL 110,163 @ $146.35
- Polen Thomas E Jr SELL 108,235 @ $146.15
- Polen Thomas E Jr M 125,680 @ $126.16
- Menziuso Peter BUY 14,258
- Feld Michael SELL 21,084 @ $147.35
- Huffines Robert Luther BUY 404 @ $149.04
- Byington Carrie L BUY 3,699 @ $149.04
- Roque Vitor BUY 8,231
Analyst estimates
FinnhubSEC filings
| Form | Filed | Description | Action |
|---|---|---|---|
| 4 | 2026-06-11 | FORM 4 | view · |
| 4 | 2026-06-03 | FORM 4 | view · |
| 4 | 2026-06-02 | FORM 4 | view · |
| 8-K | 2026-05-29 | 8-K | view · |
| 4 | 2026-05-27 | FORM 4 | view · |
| 8-K | 2026-05-20 | 8-K | view · |
| 8-K | 2026-05-12 | 8K | view · |
| 4 | 2026-05-08 | FORM 4 | view · |
| 4 | 2026-05-08 | FORM 4 | view · |
| 4 | 2026-05-08 | FORM 4 | view · |
| 10-Q | 2026-05-07 | 10-Q | view · |
| 8-K | 2026-05-07 | 8-K | view · |
| 8-K | 2026-04-29 | 8-K | view · |
| 4 | 2026-04-28 | FORM 4 | view · |
| 8-K | 2026-04-09 | 8-K | view · |
| 4 | 2026-04-06 | FORM 4 | view · |
| 8-K | 2026-04-02 | 8-K | view · |
| 4 | 2026-03-27 | FORM 4 | view · |
| 4 | 2026-03-17 | FORM 4 | view · |
| 4 | 2026-03-04 | FORM 4 | view · |
| 4 | 2026-03-04 | FORM 4 | view · |
| 4 | 2026-02-27 | FORM 4 | view · |
| 8-K | 2026-02-25 | 8-K | view · |
| 4 | 2026-02-18 | FORM 4 | view · |
| 4 | 2026-02-11 | 4 | view · |
| 8-K | 2026-02-10 | 8-K | view · |
| 10-Q | 2026-02-09 | 10-Q | view · |
| 8-K | 2026-02-09 | 8-K | view · |
| 8-K | 2026-02-09 | 8-K | view · |
| 8-K | 2026-02-05 | 8-K | view · |
| 8-K | 2026-02-05 | 8-K | view · |
| 4 | 2026-02-05 | FORM 4 | view · |
| 4 | 2026-02-05 | FORM 4 | view · |
| 4 | 2026-02-05 | FORM 4 | view · |
| 8-K | 2026-01-30 | 8-K | view · |
| 4 | 2026-01-29 | FORM 4 | view · |
| 4 | 2026-01-29 | FORM 4 | view · |
| 4 | 2026-01-29 | FORM 4 | view · |
| 4 | 2026-01-29 | FORM 4 | view · |
| 4 | 2026-01-29 | FORM 4 | view · |
| 4 | 2026-01-29 | FORM 4 | view · |
| 4 | 2026-01-29 | FORM 4 | view · |
| 4 | 2026-01-29 | FORM 4 | view · |
| 4 | 2026-01-29 | FORM 4 | view · |
| 4 | 2026-01-29 | FORM 4 | view · |
| 4 | 2026-01-29 | FORM 4 | view · |
| 4 | 2026-01-28 | FORM 4 | view · |
| 4 | 2026-01-23 | FORM 4 | view · |
| 4 | 2026-01-16 | FORM 4 | view · |
| 8-K | 2026-01-06 | 8-K | view · |
| 4 | 2026-01-06 | FORM 4 | view · |
| 4 | 2025-12-29 | FORM 4 | view · |
| DEF 14A | 2025-12-18 | DEF 14A | view · |
| 4 | 2025-12-17 | FORM 4 | view · |
| 4 | 2025-12-02 | FORM 4 | view · |
| 4 | 2025-12-02 | FORM 4 | view · |
| 4 | 2025-12-02 | FORM 4 | view · |
| 4 | 2025-12-01 | FORM 4 | view · |
| 4 | 2025-12-01 | FORM 4 | view · |
| 4 | 2025-12-01 | FORM 4 | view · |
About
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collect…